Publication - Discovery of the imidazole-derived GPR40 agonist AM-3189.

Publication in detail

Bioorg Med Chem Lett. 2015 Nov 17. pii: S0960-894X(15)30258-4. doi: 10.1016/j.bmcl.2015.11.050. [Epub ahead of print]

Discovery of the imidazole-derived GPR40 agonist AM-3189.

Ma, Z; Lin, DC; Sharma, R; Liu, J; Zhu, L; Li, AR; Kohn, T; Wang, Y; Liu, JJ; Bartberger, MD; Medina, JC; Zhuang, R; Li, L; Zhang, J; Luo, J; Wong, S; Tonn, GR; Houze, JB

Amgen Inc., South San Francisco, CA, USA.

Abstract:
As a follow-up to the GPR40 agonist AMG 837, which was evaluated in clinical trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 (13k). AM-3189 is representative of a new class of compounds with minimal CNS penetration, superior pharmacokinetic properties and in vivo efficacy comparable to AMG 837.

» Online Version

Back

Proven Track Record

The team at Ozgene has over two decades of experience creating customised knockout and knock-in mice for pivotal medical research globally. Over 400 scientific publications are based on research using Ozgene mice.

Go to Publications

Global Client Base

Ozgene generates genetically customised mice for researchers around the world. Ozgene mice can be found in 31 different countries on 5 continents from small academic institutions to multinational pharmaceutical companies.

See Client Papers

Lean Management

Ozgene is applying Lean Management principles to deliver the highest quality services and shortest lead times to our customers. The implementation of Lean Culture has already seen an improvement in our processes and timelines.